The A'-methyl-D-aspartate receptor is believed to mediate part of the ischemic neuronal damage caused by the excitatory amino acid glutamate. (+)SKF 10,047, the prototypic er-agonist, interacts with the A'-methyl-D-aspartate receptor. Therefore, we studied the neuroprotective effect of (+)SKF 10,047 on cultured rat cerebellar neurons and on CA1 hippocampal neurons of gerbils exposed to brain ischemia.
W e have recently reported that the prototypic o-agonist SKF 10,047 (Af-allylnormetazocine) as well as other benzomorphans were neuroprotective against the excitotoxic action of glutamate in our in vitro ischemia model system of cultured rat cerebellar granule cells.' 2 (+)SKF 10,047 is thought to be neuroprotective by acting as a noncompetitive antagonist at the Af-methyl-D-aspartate (NMDA) receptor channel, exerting an anticonvulsant action like MK-801 by blocking cation influx initiated by the excitatory amino acids glutamate and aspartate.
1 -3 -6 (+)SKF 10,047 also binds with high affinity to a haloperidolsensitive er-site, which is better defined by the more specific <r-ligands (+)-3-PPP[3-(3-hydroxyphenyl)-Af-(l-propyl)piperidine] and DTG (1,3-di-o-tolylguanidine). 78 We have recently reported the neuroprotective effects of (+)SKF 10,047 and MK-801 given as a pretreatment in the gerbil model of global brain ischemia. 2 In that study, we found that at equivalently neuroprotective doses, (-I-)SKF 10,047 allowed five times faster recovery from motor deficits than did MK-801, exhibited far fewer hypothermic effects, and was neuroprotective in a postischemic treatment regimen. The objectives of the present study were to extend our previous research on the mechanisms of action of (+)SKF 10,047 by examining its ability to interfere with NMDA-evoked calcium mobilization in cultured neurons and examining whether (+)SKF 10,047 exerted significant neuroprotective efficacy when given after an ischemic insult. We report the efficacy of a postischemic treatment regimen that employs the use of minipump infusion of (+)SKF 10,047 to protect against CA1 hippocampal loss.
Materials and Methods
Primary cultures of rat cerebellar neurons were prepared from 8-day-old Sprague-Dawley rat pups (Taconic Farms, Inc., Germantown, N.Y.) and used after 8 or 9 days in culture. 9 ],), cells were grown on 10.5x35 mm glass coverslips (Wheaton Industries, Millville, N.J.) in 60-mm dishes (Nunc, Roskilde, Denmark), loaded with 2 fiM fura 2-AM (Calbiochem Corp., La Jolla, Calif.) in buffer for 1 hour, and allowed to equilibrate at 37°C for 5 minutes in fresh buffer of the following millimolar composition: 154 NaCl, 5.6 KC1,2.3 CaCl, 5.6 glucose, and 8.6 Af-(2-hydroxyethyl) piperazine-Af'-(2-ethanesulfonic acid) adjusted to pH 7.4 with NaOH. Fluorescence of fura-2 in cell monolayers immersed into 2 ml buffer in a stirred cuvette was measured as previously described, 12 exposed to bilateral carotid artery occlusion for 5 minutes, and allowed to recover on the heating pad for 10 minutes. After 7 days, bilateral neuronal counts over a 750 -jiun section of the hippocampal CA1 regions stained in 0.1% thionin were determined by microscopic examination of coded slides to ensure unbiased observation. For protection studies, ( + )SKF 10,047 was dissolved in saline and administered subcutaneously as a bolus and was infused with the use of minipumps. Minipumps (Alzet model 1003D, Alza Corp., Palo Alto, Calif.) were loaded with 100 fi\ (+)SKF 10,047, activated by immersion in normal saline for 4 hours at 37°C, and implanted subcutaneously [two per gerbil to deliver a total of 270 mg/kg (+)SKF 10,047 over 3 days].
The enantiomer ( + )SKF 10,047 was obtained through the National Institute on Drug Abuse, Rockville, Md.
Data in text and figures are mean±SEM values of the indicated number of animals. Statistical analysis was performed as indicated in the figure legends; a significant difference was accepted at p< 0.05.
Results
The effect of 5 minutes' ischemia is seen in Figure 1 for vehicle-treated gerbils, in which the CA1 neuronal count was decreased to an average of 27% (44/163, n = 15) of the mean count in sham-operated animals (163) 7 days after ischemia. Administering (+)SKF 10,047 as a bolus of 15 mg/kg at 1 and 2 hours after reperfusion and as a 90 mg/kg/day infusion for 3 days was an effective posttreatment regimen (64% protection, 104/163, n = 15,/7=0.006).
In our previous investigation we never saw any evidence for ( + )SKF 10,047-induced neurotoxicity, 2 and here we examined the effects of (+)SKF 10,047 on conscious, nonischemic gerbils. There was no difference in CA1 neuronal counts when animals treated with 60 mg/kg s.c. (+)SKF 10,047 were compared with salinetreated control gerbils 7 days after injection ( Figure 2 indicated by the representative cumulative dose response shown in Figure 3A . Blockade seemed selective for the NMDA receptor channel because even with prior treatment of the neurons with 5 fiM nimodipine to inhibit voltage-sensitive L-type calcium channels, (+)SKF 10,047 still lowered the stimulated [Ca 2+ ], by 84% ( Figure 3B ). The threshold for (+)SKF 10,047 inhibition was 50 nM, and increasing concentrations increased the extent and rate of channel closure. Analysis of cumulative dose-response data yielded an IC 50 of 0.8 fM (Figure 4) . Blockade of the NMDA channel by (+)SKF 10,047 seemed complete because no further inhibition was noted after the subsequent addition of 10 fiM MK-801 ( Figure 3 ). (+)SKF 10,047 did not prevent subsequent calcium influx stimulated by kainic acid or KC1, nor did it interfere with modulation of the kainate response by quisqualic acid (Figure 3 ).
. Tracings showing inhibition by (+)SKF 10,047 of sustained intracellular calcium concentration ([Ca 2+ J t ) increases in rat cerebellar granule cells stimulated with N-methyl-D-aspartate (NMDA). A: After additions of 5 fiMglycine ( • ) and 100 n.M NMDA (A), (+)SKF 10,047 was sequentially added to trace 1 (downward arrows) at increasing micromolar concentrations shown. Subsequent additions included 10 pM MK-801, 100 fiM kainic acid (KA), 100 ixM quisqualic acid (QA), and 30 mM KCl. B: Neurons received 5 n-Meach ofglycine and nimodipine before addition of 100 pMNMDA (A). (+)SKF 10,047 was added as in A (upward arrows, trace 2) at increasing micromolar concentrations shown, followed by same additions as in A.

FIGURE 4. Plot showing blockade by (+)SKF 10,047 of 'H-methyl-D-aspartate (NMDA)/gfycine-induced increases in intracellular calcium concentration ([
Discussion
The interruption of cell calcium homeostasis by excitatory amino acids is considered to be an important initiator of excitotoxic damage, 21 especially in delayed neuronal death. In cerebellar granule cells, NMDA causes sustained increases in [Ca 2+ ],, 13 -15 as clearly shown in the present study. The primary influx is through the receptor-associated channel, with secondary influx through voltage-sensitive channels that are inhibited by nifedipine. 13 The agonist-operated calcium channel flux can be blocked rapidly by MK-801, 13 ' 15 as we have shown here for (+)SKF 10,047. The IC 50 of 0.8 fiM and the cumulative levels of (+)SKF 10,047 needed to totally block the channel (16.65 /uM, Figure 4 ) reflect the levels we reported for protection against glutamateinduced excitotoxicity.
1 The ( + )SKF 10,047 effect was selective for only the NMDA subtype of glutamate receptor because, as reported for MK-801, 13 subsequent stimulation of neurons with kainate caused immediate calcium influx and prior treatment with nifedipine did not alter the potency of (+)SKF 10,047. Similarly, the inhibitory response at the kainate receptor by quisqualate, which has been assessed in a variety of ways in these cells, 152223 persisted after the addition of (+)SKF 10,047, again supporting the selectivity of (-I-)SKF 10,047's action at the NMDA receptor. These results strengthen our previous suggestion that benzomorphan cross-reactivity at NMDA receptors affords neuroprotection with diminished side effects. 2 Although the protective mechanism of (+)SKF 10,047 in vitro indicates efficacy at, and selectivity for, the NMDA receptor, NMDA receptor activation in vivo is not the only mechanism involved in selective neuronal vulnerability. Other factors, such as non-NMDA receptors, must be involved in neuronal death in vivo because noncompetitive inhibitors such as (+)SKF 10,047 do not provide total neuroprotection 2 ( Figure 1 ).
The results of the minipump protection study, in which treatment was delayed until 1 hour after reperfusion, reinforces our previous findings that (+)SKF 10,047 is an effective neuroprotectant even when treatment is initiated after ischemia. 2 The neuroprotective effect of the minipump treatment was the same as that of our previous posttreatment regimen of 15 mg/kg at 15 minutes and 1 hour and 30 mg/kg at 2, 4, and 6 hours, which produced no significant decrease in temporalis muscle temperature until after 4 hours of treatment. 2 The minipump was implanted 20 minutes after the 100-minute therapeutic window of opportunity for reversal of delayed neuronal injury with halothane, an inhibitor of postischemic hyperthermia. 20 - 24 The neuroprotective effect of the minipump treatment regimen further supports a pharmacological effect for (+)SKF 10,047 independent from hypothermia. Drug-induced hypothermia is an important consideration in neuroprotection studies because many authors have shown that simply lowering brain temperature by only 2°C prevents neuronal damage after forebrain ischemia 17   -20   -25   - 27 while others have reported the hypothermic protection afforded by MK-801. 1819 Other studies of the temperature effects of SKF 10,047 in mice and rats have shown mostly no effect, with occasional hyperthermia. 28 -29 However, doses of (+)SKF 10,047 higher than used here (80 mg/kg) have been reported to produce acute hypothermia in rats 30 as we have reported for 60 mg/kg in gerbils. 31 Because acute administration of (+)SKF 10,047 at 5-40 mg/kg s.c. produced no temperature effects in rats 30 and we saw either no hypothermia or swift resolution (15-30 minutes) of hypothermia in gerbil brain, 2 neuroprotection by (+)SKF 10,047 is likely to be independent of hypothermia.
We also do not envision a neuroprotective effect in vivo by increasing cerebral blood flow because (+)SKF 10,047 causes only small increases in heart rate and mean arterial blood pressure in conscious dogs 32 and has no contractile effect at up to 100 fiM in rat tail artery. 33 In fact, (+)SKF 10,047 potentiated norepinephrine-induced contractions in rat tail artery 33 and, in general, benzomorphans have been shown to constrict isolated canine cerebral vessels, but only at concentrations around 0.1-1 mM. 34 Therefore, if (+)SKF 10,047 has an effect on cerebral vessels, one could expect only vasoconstriction and reduced blood flow. Although noncompetitive inhibitors of the NMDA receptor have been reported to cause neuropathologic changes such as vacuole formation 35 and stimulation of heat shock protein HSP72 36 in rat brain, we observed no pathological changes in the hippocampal CA1 regions of gerbils receiving up to 60 mg/kg ( + )SKF 10,047. Therefore, this class of noncompetitive NMDA receptor inhibitors may be better tolerated.
These results offer further evidence that the neuroprotective effects of (+)SKF 10,047 are manifested at the NMDA receptor and that this class of compound may prove useful in the treatment of cerebral ischemia and stroke.
